Join Free
SI Premium
RSS Feeds
E-mail Alerts
Portfolio
Login
Recent Quotes
View Full List
My Watchlist
Create Watchlist
Indicators
DJI
Nasdaq Composite
SPX
Gold
Crude Oil
Markets
Stocks
ETFs
Tools
Overview
News
Currencies
International
Treasuries
Gilead Sciences
(NQ:
GILD
)
64.27
+0.19 (+0.30%)
Official Closing Price
Updated: 4:15 PM EDT, May 31, 2024
Add to My Watchlist
Quote
Overview
Detailed Quote
Charting
Historical Prices
News
All News
News Headlines
Press Releases
Research
Quarterly Reports
Insider Filings
Other Filings
Press Releases about Gilead Sciences
< Previous
1
2
...
9
10
11
12
13
14
15
16
Next >
Charting a Career to Help Reduce Health Inequity: Porscha's Story
February 18, 2022
SOURCE: Gilead Sciences
Via
3BL Media
New Clinical Data Support the Sustained Efficacy of Long-acting Lenacapavir, Gilead’s Investigational HIV-1 Capsid Inhibitor
February 16, 2022
From
Gilead Sciences, Inc.
Via
Business Wire
Gilead Sciences Invests in Research for COVID-19 Treatments for All Ages
February 16, 2022
SOURCE: Gilead Sciences
Via
3BL Media
Exposures
COVID-19
Phase 2/3 Interim Data Evaluating the Safety, Tolerability and Clinical Outcomes of Veklury® (Remdesivir) in Pediatric Patients With COVID-19 Presented at CROI 2022
February 11, 2022
From
Gilead Sciences, Inc.
Via
Business Wire
Biktarvy® Demonstrates High Efficacy and Durable Viral Suppression at Five Years, in Treatment-Naïve Adults
February 11, 2022
From
Gilead Sciences, Inc.
Via
Business Wire
Veklury® (Remdesivir) Retains Antiviral Activity Against Omicron, Delta and Other Emergent SARS-CoV-2 Variants in Multiple In Vitro Studies
February 11, 2022
From
Gilead Sciences, Inc.
Via
Business Wire
Ending HIV-Related Stigma in the Southern United States: Gina's Story
February 11, 2022
SOURCE: Gilead Sciences
Via
3BL Media
What World Cancer Day Means to Me
February 09, 2022
SOURCE: Gilead Sciences
Via
3BL Media
Gilead to Present Latest Antiviral Research and Development Data at CROI 2022 Addressing Urgent Global Needs
February 08, 2022
From
Gilead Sciences, Inc.
Via
Business Wire
Living Well With Hepatitis B: Lai's Journey
February 08, 2022
SOURCE: Gilead Sciences
Via
3BL Media
Gilead Sciences Named a Best Place to Work for LGBTQ+ Equality in 2022
February 04, 2022
SOURCE: Gilead Sciences
Via
3BL Media
Gilead Sciences to Present at Upcoming Investor Conferences
February 03, 2022
From
Gilead Sciences, Inc.
Via
Business Wire
Gilead Sciences Announces 2.8 Percent Increase in First Quarter 2022 Dividend
February 01, 2022
From
Gilead Sciences, Inc.
Via
Business Wire
Gilead Sciences Announces Fourth Quarter and Full Year 2021 Financial Results
February 01, 2022
From
Gilead Sciences, Inc.
Via
Business Wire
Inside the Innovation: Pharmaceutical Development and Manufacturing Leaders Share Experiences
February 01, 2022
SOURCE: Gilead Sciences
Via
3BL Media
U.S. FDA Approves New Label Update for CAR T-Cell Therapy Yescarta® Showing Prophylactic Steriod Use Improves Management of Cytokine Release Syndrome
January 31, 2022
From
Gilead Sciences, Inc.
Via
Business Wire
HIV in the Time of COVID-19: The Case for Investment
January 28, 2022
SOURCE: Gilead Sciences
Via
3BL Media
Exposures
COVID-19
Improving HIV Care With Telehealth
January 26, 2022
SOURCE: Gilead Sciences
Via
3BL Media
Exposures
COVID-19
Gilead Announces Partial Clinical Hold for Studies Evaluating Magrolimab in Combination With Azacitidine
January 25, 2022
From
Gilead Sciences Inc.
Via
Business Wire
FDA Approves Veklury® (Remdesivir) for the Treatment of Non-Hospitalized Patients at High Risk for COVID-19 Disease Progression
January 21, 2022
From
Gilead Sciences, Inc.
Via
Business Wire
Gilead Policy Papers Show Pandemic's Impact on HIV Prevention and Care
January 21, 2022
SOURCE: Gilead Sciences
Via
3BL Media
Exposures
COVID-19
Promising Research in Fight Against Breast Cancer Being Amplified by an Active Biotech Sector
January 20, 2022
FN Media Group Presents USA News Group News Commentary Vancouver, BC –January 20, 2021 – USA News Group – As the 2021 San Antonio Breast Cancer Symposium (SABCS) comes to a close, many of this year’s...
Via
FinancialNewsMedia
Gilead Sciences to Release Fourth Quarter & Full Year 2021 Financial Results on Tuesday, February 1, 2022
January 18, 2022
From
Gilead Sciences, Inc.
Via
Business Wire
Former Clinician Alain Chan Finds Opportunity to Expand Impact, Develop Personally and Professionally
January 14, 2022
SOURCE: Gilead Sciences
Via
3BL Media
Developing Future Social Justice Leaders at Tougaloo College
January 11, 2022
SOURCE: Gilead Sciences
Via
3BL Media
Gilead Announces Clinical Trial Collaborations With Merck to Evaluate Trodelvy® in Combination With KEYTRUDA® in First-Line Metastatic Non-Small Cell Lung Cancer
January 10, 2022
From
Gilead Sciences, Inc.
Via
Business Wire
Gilead's Rohini Mehtani, Ph.D. Reflects on The Importance of ASH21
January 04, 2022
SOURCE: Gilead Sciences
Via
3BL Media
Russian Foundation Provides Career Guidance for Teens Living With HIV
December 28, 2021
SOURCE: Gilead Sciences
Via
3BL Media
Gilead Announces New England Journal of Medicine Publication of Data Demonstrating Veklury® (Remdesivir) Significantly Reduced Risk of Hospitalization in High-Risk Patients With COVID-19
December 22, 2021
From
Gilead Sciences, Inc.
Via
Business Wire
Gilead Sciences and Breast Cancer Awareness Month
December 22, 2021
SOURCE: Gilead Sciences
Via
3BL Media
< Previous
1
2
...
9
10
11
12
13
14
15
16
Next >
Data & News supplied by
www.cloudquote.io
Stock quotes supplied by Barchart
Quotes delayed at least 20 minutes.
By accessing this page, you agree to the following
Privacy Policy
and
Terms and Conditions
.